Cristina Bugés

Dr. Cristina Bugés


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAnna Pous
Anna Pous
LNLucía Notario
Lucía Notario
CHCinta Hierro
Cinta Hierro
LLLaura Layos
Laura Layos
CBCristina Bugés
Cristina Bugés
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic disease has improved the prognosis of this subset of patients. However, gastric cancer still has high mortality rates and urgently requires new treatment strategies. The combination of immunotherapy with HER2-targeted therapies has shown synergistic effects in preclinical models, this being the rationale behind exploring this combination in clinical trials in locally advanced and metastatic settings. Additionally, the irruption of antibody–drug conjugates and other novel HER2-targeted agents has led to the development of numerous clinical trials showing promising results. This review presents the molecular mechanisms supporting the use of HER2-targeted drugs in combination with immunotherapy and provides an overview of the therapeutic scenario of HER2-positive disease. We focus on the role of immunotherapy but also summarize emerging therapies and combinations under clinical research that may change the standard treatment in HER-2 positive disease in the future.

11 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Vicenç Ruiz de PorrasVicenç Ruiz de Porras
Vicenç Ruiz de Porras
SBSara Bystrup
Sara Bystrup
SHSara Cabrero-De Las Heras
Sara Cabrero-De Las Heras
EMEva Musulen
Eva Musulen
LPLuis Palomero
Luis Palomero
EMEva Martínez-Balibrea
Eva Martínez-Balibrea
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.

1 March 2015 in Clinical Lung Cancer
Verified
Journal Article
Closed access
CBCristina Bugés
Cristina Bugés
ECEnric Carcereny
Enric Carcereny
TMTeresa Moran
Teresa Moran
ACAndrés Felipe Cardona
Andrés Felipe Cardona
NRNoemi Reguart
Noemi Reguart
RRRafael Rosell
Rafael Rosell